Overview
- 19 inspections across 17 sites are on record.
- 8 Form 483 observations are attributed to this investigator.
- Most recent recorded activity is 2020-02-14.
At a glance
Inspections
19
Sites
17
Observations
8
Career since
Mar 2016
Recent inspections
Most recent inspections in the published record.
| Site | Date | Category | Form 483 |
|---|---|---|---|
| Labcorp Early Development Laboratories, Inc. | 14 Feb 2020 | Human Drugs | |
| Solaris Pharma Corporation | 9 Jan 2020 | Human Drugs | |
| inVentiv Health Clinical Lab, Inc. | 8 Nov 2019 | Human Drugs | |
| UNC Clinical Pharmacology and Analytical Chemistry Lab | 12 Jul 2019 | Human Drugs | |
| Integris Bioservices LLC | 13 Jun 2019 | Human Drugs |
Sites inspected
Labcorp Early Development Laboratories, Inc.Madison, United States1 insp.
Solaris Pharma CorporationSomerset, United States1 insp.
inVentiv Health Clinical Lab, Inc.Princeton, United States1 insp.
UNC Clinical Pharmacology and Analytical Chemistry LabChapel Hill, United States1 insp.
Integris Bioservices LLCOlathe, United States1 insp.
Co-investigators
Investigators who share inspections with this person.
Kara A Scheibner2 shared
Peter R Lenahan1 shared
Denise L Burosh1 shared
Li-Hong Yeh1 shared
Vanessa E Coulter1 shared
Himanshu Gupta1 shared
Nina Yang1 shared
Jonathan R Campos1 shared
Srinivas Chennamaneni1 shared
Yvette M Lacour-Davis1 shared
Full investigator report
Get the verbatim findings behind Xiaohan Cai's 8 observations
Source 483 PDFs, verbatim observations, and how each site responded, so your team knows what they cite before they arrive.
- New inspections and Form 483s, mapped to the CFR citation
- Warning letter outcomes, and the citation patterns they repeat
- Their co-investigators, so no surprises about who shows up on site